6533b855fe1ef96bd12afe15

RESEARCH PRODUCT

Synthesis of curcumin derivatives and analysis of their antitumor effects in triple negative breast cancer (TNBC) cell lines

Manuela LabbozzettaTania M. G. SalernoMonica NotarbartoloPaola BonaccorsiAnna BarattucciPaola Poma

subject

antiproliferative activitySubstituentPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441antioxidant activityprooxidant activitylcsh:Pharmacy and materia medicapro-apoptotic activity03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug DiscoveryCytotoxic T cellNF-κB inhibitionAntioxidant activity Antiproliferative activity NF-κB inhibition Pro-apoptotic activity Prooxidant activity Sulfenic acidIC50Triple-negative breast cancer030304 developmental biology0303 health sciencesCommunicationlcsh:Rsulfenic acidchemistryCell culture030220 oncology & carcinogenesisCancer researchCurcuminSettore BIO/14 - FarmacologiaMolecular MedicineSulfenic acidLead compound

description

We analyzed antitumor effects of a series of curcumin analogues. Some of them were obtained by reaction of substitution involving the two phenolic OH groups of curcumin while the analogues with a substituent at C-4 was prepared following an original procedure that regards the condensation of benzenesulfenic acid onto the nucleophilic central carbon of the curcumin skeleton. We analyzed cytotoxic effects of such derivatives on two TNBC (triple negative breast cancer) cell lines, SUM 149 and MDA-MB-231, but only three of them showed an IC50 in a lower micromolar range with respect to curcumin. We also focused on these three derivatives that in both cell lines exhibited a higher or at least equivalent pro-apoptotic effect than curcumin. The analysis of molecular mechanisms of action of the curcumin derivatives under study has highlighted that they decreased NF-κB transcriptional factor activity, and consequently the expression of some NF-κB targets. Our data confirmed once again that curcumin may represent a very good lead compound to design analogues with higher antitumor capacities and able to overcome drug resistance with respect to conventional ones, even in tumors difficult to treat as TNBC.

yearjournalcountryeditionlanguage
2019-10-01
10.3390/ph12040161http://hdl.handle.net/11570/3150824